How to interpret antipsychotic drug levels in schizophrenia: when labs mislead, when levels help adherence and toxicity checks, and why serial monitoring matters.
|Articles|April 29, 2011
Quiz on Schizophrenia
Author(s)Psychiatric Times Editors
Listen
0:00 / 0:00
Key Takeaways
- Cognitive rehabilitation is positioned as a potentially modifiable lever in schizophrenia, with emphasis on whether cognitive change yields optimal functional outcome improvements.
- Comorbid obsessive-compulsive disorder in schizophrenia is highlighted as an epidemiologic and clinical consideration, prompting recall of prevalence estimates reported across studies.
Does cognitive rehabilitation provides optimal improvements in functional outcome for patients with schizophrenia? What percentage of patients with schizophrenia who have comorbid obsessive compulsive disorder? This and more in this week's quiz.
Advertisement
Does cognitive rehabilitation provides optimal improvements in functional outcome for patients with schizophrenia? What percentage of patients with schizophrenia who have comorbid obsessive compulsive disorder? This and more in this week's quiz.
Advertisement
Related to this article
Therapeutic drug monitoring takes guesswork out of antipsychotic care—spotting nonadherence, guiding dose targets, and defining response thresholds and the “point of futility” in schizophrenia.
FDA approves monthly subcutaneous olanzapine LAI Weltruza, expanding schizophrenia treatment options and renewing debate on making long-acting injectables routine.
Once-monthly subcutaneous olanzapine LAI requires no loading doses, oral supplementation, or post-injection monitoring, based on phase 3 SOLARIS data.
Neurosterix advances NTX-253, an oral M4 PAM, into phase 2 for schizophrenia after phase 1 shows promising safety and pharmacokinetics.
Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.
Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
Despite previous failure of PDE10A inhibitor drugs to demonstrate antipsychotic effects in clinical trials, a new "improved" iteration has met phase 2 trial endpoints.
Advertisement
Advertisement